KalVista Pharmaceuticals Inc (NASDAQ: KALV) kicked off on Monday, down -7.51% from the previous trading day, before settling in for the closing price of $11.85. Over the past 52 weeks, KALV has traded in a range of $7.30-$17.28.
Healthcare Sector giant saw their annual sales slid by -17.63% over the last five years. While this was happening, its average annual earnings per share was recorded 87.71%. With a float of $37.87 million, this company’s outstanding shares have now reached $50.34 million.
KalVista Pharmaceuticals Inc (KALV) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of KalVista Pharmaceuticals Inc is 25.04%, while institutional ownership is 88.67%. The most recent insider transaction that took place on Sep 08 ’25, was worth 115,537. In this transaction CHIEF EXECUTIVE OFFICER of this company sold 7,294 shares at a rate of $15.84, taking the stock ownership to the 395,189 shares. Before that another transaction happened on Aug 25 ’25, when Company’s Chief Commercial Officer sold 1,480 for $13.42, making the entire transaction worth $19,862. This insider now owns 32,291 shares in total.
KalVista Pharmaceuticals Inc (KALV) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 10/31/2024, the organization reported -0.91 earnings per share (EPS), higher than consensus estimate (set at -0.91) by -0. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.92 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 87.71% per share during the next fiscal year.
KalVista Pharmaceuticals Inc (NASDAQ: KALV) Trading Performance Indicators
Take a look at KalVista Pharmaceuticals Inc’s (KALV) current performance indicators. Last quarter, stock had a quick ratio of 5.37. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 387.23.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.00, a number that is poised to hit -1.00 in the next quarter and is forecasted to reach 0.91 in one year’s time.
Technical Analysis of KalVista Pharmaceuticals Inc (KALV)
Analysing the last 5-days average volume posted by the [KalVista Pharmaceuticals Inc, KALV], we can find that recorded value of 1.59 million was better than the volume posted last year of 0.87 million. As of the previous 9 days, the stock’s Stochastic %D was 12.55%.
During the past 100 days, KalVista Pharmaceuticals Inc’s (KALV) raw stochastic average was set at 15.17%, which indicates a significant increase from 6.17% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.60 in the past 14 days, which was lower than the 0.76 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $13.30, while its 200-day Moving Average is $11.93. Now, the first resistance to watch is $11.78. This is followed by the second major resistance level at $12.60. The third major resistance level sits at $13.11. If the price goes on to break the first support level at $10.44, it is likely to go to the next support level at $9.93. Now, if the price goes above the second support level, the third support stands at $9.11.
KalVista Pharmaceuticals Inc (NASDAQ: KALV) Key Stats
The company with the Market Capitalisation of 553.74 million has total of 50,523K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -183,440 K annual income. Company’s last quarter sales were recorded 1,430 K and last quarter income was -60,100 K.
